BIOAF (Bioasis Technologies) Beta: 357.8354 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOAF Bioasis Technologies Inc BIOAF
12 GF Score
Price $0.00
View Full Analysis

What is Bioasis Technologies Beta?

Bioasis Technologies BIOAF 12 Beta is 357.8354 as of Jul. 15, 2026. GuruFocus rates BIOAF with a GF Score™ of 12/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-15), Bioasis Technologies's Beta is 357.8354.


Bioasis Technologies  (OTCPK:BIOAF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Bioasis Technologies Beta Related Terms


Bioasis Technologies Beta Historical Data

* Premium members only.

The historical data trend for Bioasis Technologies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioasis Technologies Beta Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 -0.38 -0.83 0.35 0.39

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.39 0.65 0.60 0.54

BIOAF vs VRTX, REGN, SGEN: Beta Comparison

For the Biotechnology subindustry, Bioasis Technologies's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Beta distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Beta falls into.


BIOAF
12GF Score
Bioasis Technologies Inc BIOAF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioasis Technologies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 357.8354 mean?
Bioasis Technologies (BIOAF) has a Beta of 357.8354 as of Jul. 15, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Bioasis Technologies and its competitors.
Is Bioasis Technologies' Beta too high?
Bioasis Technologies' current Beta is 357.8354. Overall, Bioasis Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioasis Technologies' Beta compare to VRTX and REGN?
Bioasis Technologies' Beta of 357.8354 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Bioasis Technologies and its competitors. Bioasis Technologies's current Beta is 357.8354. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioasis Technologies stock overvalued right now?
Bioasis Technologies (BIOAF) has a current Beta of 357.8354. The current Beta is 357.8354. Bioasis Technologies' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Bioasis Technologies (BIOAF), the current Beta is 357.8354 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioasis Technologies Business Description

Address 157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's xB3 program describes its proprietary carrier, p97, and components thereof, to deliver therapeutics across the blood-brain barrier (BBB).
12GF Score

Get the complete analysis for BIOAF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price